Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

Gene therapy experts and advocates warning of the sector’s many challenges found a receptive audience in FDA leadership at a ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool's ...

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...